The evolution of ideas about the diagnosis and treatment of various phenotypes of chronic heart failure in type 2 diabetes mellitus

Abstract

Despite the successes achieved in diagnosis and treatment, HF, regardless of the phenotype, remains one of the significant problems in the health sector, due to the high incidence, frequency of hospitalization, disability and mortality. In turn, patients with both type 2 diabetes and prediabetes are a vulnerable group in terms of the development of CHF. CH-sFV therapy has been focused for several decades on the treatment of concomitant diseases such as type 2 diabetes, hypertension, coronary heart disease, obesity and, if necessary, initiation of diuretic therapy to improve the quality of life. However, to date, great progress has been made in the treatment of HF-sFV. All guidelines for the management of patients with HF, based on the results of large randomized trials, postulate that iNGLT2 types are the basic drugs for the treatment of patients with HF, regardless of PV. Algorithms of specialized medical care for patients with diabetes recommend the appointment of iNGLT type 2 in the presence or high risk of developing CHF and/or CKD, regardless of the HbA1c level, in patients with type 2 diabetes to reduce the risk of hospitalization for HF, cardiovascular events and reduce the risks of CKD progression.